On September 30, CSPC PHARMA rose 3.48% in regular trading, trading at 9.81 HKD/share, with turnover of approximately 113 million HKD. The gain was primarily driven by two research and development milestones announced on September 29.

The company disclosed that its independently developed recombinant herpes zoster vaccine SYS6052 received approval from the U.S. Food and Drug Administration to begin clinical trials in the United States. The vaccine, designed to prevent herpes zoster and related complications in adults aged 50 and older, features a varicella-zoster virus gE protein antigen combined with a proprietary novel nano-adjuvant system. SYS6052 had previously received approval from China's NMPA to commence domestic clinical trials in July. This marks CSPC PHARMA's first U.S. clinical trial approval in the recombinant protein vaccine space, formally launching the company's global preventive vaccine strategy.

On the same day, the company also announced the initiation of a Phase Ib clinical trial in China for JMT206 Injection, a weight management drug targeting obese or overweight adult patients. The dual pipeline developments come amid a broader wave of recent clinical progress, including positive Phase III topline results for its lung cancer combination therapy and breakthrough therapy designation for its ADC drug SYS6010.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)